<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763072</url>
  </required_header>
  <id_info>
    <org_study_id>C-16-EV09</org_study_id>
    <nct_id>NCT02763072</nct_id>
  </id_info>
  <brief_title>A Single-Center 2-Arm Study for Lentigines on the Hands</brief_title>
  <official_title>A Single-Center 2-Arm Study of the Enlighten and Excel V Laser for Lentigines on the Hands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety in a clinic setting of
      two laser systems for improvement of lentigines on the hands.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety in a clinic setting of
      two laser systems for the treatment of lentigines (liver spots, age spots, or dark sun spots)
      on the hands.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Hand Lentigines</measure>
    <time_frame>Four weeks post final laser treatment.</time_frame>
    <description>Percent reduction in the number of hand lentigines at 4 weeks post-final treatment as assessed by blinded reviewers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aesthetic Improvement</measure>
    <time_frame>Four weeks post final laser treatment.</time_frame>
    <description>Degree of improvement in both the Overall appearance and the Skin Texture of the hands at 4 weeks post-final treatment as assessed by blinded reviewers using the Physician's Global Assessment scale: +4=Very Significant Improvement(&gt; or =75%),+3=Significant Improvement(51 - 75%), +2=Moderate Improvement(26 - 50%), +1=Mild Improvement(5 - 25%) and 0=No Change(&lt;5%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction of laser treatment</measure>
    <time_frame>4 weeks post-final treatment</time_frame>
    <description>Subject satisfaction of laser treatment outcome at 4 weeks post-final treatment using a subject questionnaire: Very Satisfied, Satisfied, Neutral, Dissatisfied, and Very Dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Rating of laser treatment</measure>
    <time_frame>4 weeks post-final treatment</time_frame>
    <description>Rating of the overall laser treatment procedure at 4 weeks post-final treatment by Subject using a questionnaire: +4=Very Significant Improvement(&gt; or =75%),+3=Significant Improvement(51 - 75%), +2=Moderate Improvement(26 - 50%), +1=Mild Improvement(5 - 25%) and 0=No Improvement(&lt;5%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Lentigines</condition>
  <arm_group>
    <arm_group_label>Picosecond Q-switched Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects will receive one treatment with a dual wavelength 532 nm KTP and/or 1064 nm Nd: YAG picosecond pulse duration laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KTP Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 subjects will receive up to four treatments with a dual wavelength 532nm KTP long pulsed laser and/or 1064 nm Nd: YAG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picosecond Q-switched Laser</intervention_name>
    <description>One Enlighten treatment</description>
    <arm_group_label>Picosecond Q-switched Laser</arm_group_label>
    <arm_group_label>KTP Laser</arm_group_label>
    <other_name>Cutera Enlighten</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KTP Laser</intervention_name>
    <description>Up to four Excel V treatments</description>
    <arm_group_label>Picosecond Q-switched Laser</arm_group_label>
    <arm_group_label>KTP Laser</arm_group_label>
    <other_name>Cutera Excel V</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or Male, 30-90 years of age (inclusive).

          2. Fitzpatrick Skin Type I - III.

          3. Desires non-invasive and non-ablative treatment of lentigines on the hand(s).

          4. Have 4 or more lentigines on the hand(s).

          5. Subject must be able to read, understand and sign the Informed Consent Form.

          6. Must be willing and able to adhere to the treatment and follow-up schedule and
             post-treatment care instructions.

          7. Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or
             higher on the treatment area every day for the duration of the study, including the
             follow-up period.

          8. Willing to have digital photographs taken of the treatment area and agree to use of
             photographs for presentation, educational or marketing purposes.

          9. Agree to not undergo any other procedure(s) for treatment of lentigines during the
             study, including but not limited to chemical peel, laser and light based device
             treatment, and home-use device treatment.

         10. Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid
             filler or other dermal filler to the treatment area during the study.

        Exclusion Criteria:

          1. Participation in a clinical trial of another device or drug in the target area within
             6 months prior to enrollment or during the study.

          2. Any type of prior cosmetic treatment to the target area within 6 months of study
             participation, such as laser or light-based procedures or surgery.

          3. Systemic use of retinoid, such as isotretinoin, within 6 months of study
             participation.

          4. Use of topical medications on the hands, such as antibiotics, benzoyl peroxide,
             retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing
             dihydroxyacetone or alpha-hydroxy with concentration &gt; 8%, within 1 month of
             participation.

          5. History of malignant tumors in the target area.

          6. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large
             moles.

          7. Pregnant.

          8. Having an infection, dermatitis, or a rash in the treatment area.

          9. History of keloid scarring, hypertrophic scarring or of abnormal wound healing.

         10. Any use of medication that is known to increase sensitivity to light according to
             investigator's discretion.

         11. History of radiation to the treatment area or undergoing systemic chemotherapy for the
             treatment of cancer.

         12. History of pigmentary disorders, particularly tendency for hyper- or
             hypo-pigmentation.

         13. Anytime in life, having have used gold therapy (gold salts) for disorders such as
             rheumatologic disease or lupus.

         14. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

         15. In the opinion of the investigator, any physical or mental condition which might make
             it unsafe for the subject to participate in this study or which requires systematic
             therapy that could interfere with this research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Stankiewicz, MD FAAD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DuPage Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

